Justin Klee (L) and Josh Cohen (Amylyx)

Ad­comm votes 7-2 in fa­vor of Amy­lyx's ALS drug on sec­ond take. But first the co-CEOs had to make a pledge

Sec­ond time’s the charm for Amy­lyx and its ex­per­i­men­tal ALS drug. In an un­usu­al twist, out­side ex­perts on an FDA ad­vi­so­ry com­mit­tee vot­ed 7-2 in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA